We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
8 own
11 watching
Current Price
$4.2
$0.16
(3.96%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
166.22M
52-Week High
17.26
52-Week Low
2.36
Average Volume
0.17M
Dividend Yield
--
P/E Ratio
--
Market Capitalization166.22M
52-Week High17.26
52-Week Low2.36
Average Volume0.17M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Collectively, our founders and management team have a decades-long heritage of identifying and characterizing resistance mechanisms in oncology, having discovered and developed groundbreaking medicines at companies such as Ignyta, Medivation, Aragon and Genentech. At ORIC, our fully integrated discovery and development team is advancing a diverse pipeline of innovative therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. We were incorporated in Delaware in August 2014. Our principal executive offices are located at 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080. Our telephone number is (650) 388-5600.Our website address is www.oricpharma.com.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
30days ago
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a preclinical poster presentation on ORIC-533 ...
Ticker Report
8 months ago
ORIC Pharmaceuticals (NASDAQ:ORIC Get Rating) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zacks, ORIC Pharmaceuticals Inc. is a clinical stage ...
Benzinga
8 months ago
read more...
PR Newswire
8 months ago
Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners? Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners? PR Newswire...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$4.2
$0.16
(3.96%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00